Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A. Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero, Jalid Sehouli, Alain Lortholary, Gunnar Kristensen, Christian Jackisch, Florence Joly, Chris Brown, Nathalie Le Fur, Andreas Du Bois

Research output: Contribution to journalArticle

Abstract

Purpose: This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC). Patients and Methods: Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based therapies were randomly assigned by stratified blocks to CD (carboplatin area under the curve [AUC] 5 plus PLD 30 mg/m2) every 4 weeks or CP (carboplatin AUC 5 plus paclitaxel 175 mg/m2) every 3 weeks for at least 6 cycles. Primary end point was progressionfree survival (PFS); secondary end points were toxicity, quality of life, and overall survival. Results: Overall 976 patients were recruited. With median follow-up of 22 months, PFS for the CD arm was statistically superior to the CP arm (hazard ratio, 0.821; 95% CI, 0.72 to 0.94; P = .005); median PFS was 11.3 versus 9.4 months, respectively. Although overall survival data are immature for final analysis, we report here a total of 334 deaths. Overall severe nonhematologic toxicity (36.8% v 28.4%; P <.01) leading to early discontinuation (15% v 6%; P <.001) occurred more frequently in the CP arm. More frequent grade 2 or greater alopecia (83.6% v 7%), hypersensitivity reactions (18.8% v 5.6%), and sensory neuropathy (26.9% v 4.9%) were observed in the CP arm; more hand-foot syndrome (grade 2 to 3, 12.0% v 2.2%), nausea (35.2% v 24.2%), and mucositis (grade 2-3, 13.9% v 7%) in the CD arm. Conclusion: To our knowledge, this trial is the largest in recurrent ovarian cancer and has demonstrated superiority in PFS and better therapeutic index of CD over standard CP.

Original languageEnglish
Pages (from-to)3323-3329
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number20
DOIs
Publication statusPublished - Jul 10 2010

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse'. Together they form a unique fingerprint.

Cite this